Press Releases


Recent:

VisionGate® Showcases Advances in Lung Cancer Early Detection and Treatment at the World Conference on Lung Cancer
Press Release, October 19, 2017

VisionGate Hires Prominent Pathologist as Medical Director, VisionGate, Inc.
Press Release, June 7, 2017

17th World Conference on Lung Cancer: VisionGate Will Speak Twice!

VisionGate to Speak for The Exclusive Piper Jaffray Conference at The Lotte New York Palace Hotel

VisionGate Hires Renowned Chief Medical Officer Dr. Javier Zulueta

VisionGate’s LuCED® Test and New Drug Therapy to Prevent Lung Cancer Demonstrate Promise in National Surveys of Pulmonologists

VisionGate’s Alan Nelson Named Academy of Inventors Fellow

VisonGate Receives Strategic Investment from Trinnovate Ventures

VisionGate to Present at Leerink Partners Global Healthcare Conference

Lung Cancer Pioneers Create Lung Cancer Eradication Pact: VisionGate Acquires Exclusive Rights to University of Colorado’s Chemoprevention Drug Iloprost

VisionGate’s First Product, LuCED®, Shows Promise for Screening of Lung Cancer:  Company Presents Blinded Trial Data at WCLC 2015

Two articles published in Cancer Cytopathology demonstrate potential for lung cancer screening using sputum

World renowned surgeon Dr. Harvey Pass joins VisionGate’s Medical Advisory Board

Dignity Health in Arizona Invests in VisionGate

VisionGate® Wins Two Gold Awards in the Best in Biz Awards 2014

New Data Demonstrates VisionGate’s LuCED® Test Able to Detect Early Lung Cancer — Even from Small Nodules

VisionGate’s Scarlett Spring to Present at White Hat Life Science Investor Conference

VisionGate Adds Three Prominent Board Directors

New Study Shows High Sensitivity and Specificity for VisionGate’s LuCED® Test to Help Detect Early Lung Cancer

VisionGate to Present Early Lung Cancer Detection Data at ASCO

VisionGate presents clinical data at IASLC meeting showing its Cell-CT 3D imaging platform detects lung cancer with high sensitivity and specificity

VisionGate reports advances in its Cell-CT™ automated 3-D cell analysis platform at ASC 2012 Scientific Meeting

 

Archived:

2012:

VisionGate uses $2.6 million NIH Grant to achieve full automation of Cell-CT 3D imaging system for early diagnosis of cancer

2011:

VisionGate named winner of Arizona Governer’s celebration of Innovation Award for start-up  company innovator of the year

VisionGate, Inc. closes $2 million financing and announces collaboration to evaluate its 3D Cell Imaging platform for early lung cancer detection

VisionGate, Inc. will present data showing how adjunctive use of its LuCED test can improve the utility of low dose x- ray computed tomography (CT) screening for the early detection of lung cancer in high risk individuals

2010:

VisionGate recipient of qualifying therapeutic discovery project program

The City of Phoenix, in partnership with VisionGate, Inc., is opening the world’s first biomedical 3D cellular imaging lab

 


This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.


Copyright 2017 - VisionGate, Inc.